INTEGRATING RHEUMATOLOGY AND ONCOLOGY: AUTOIMMUNE COMPLICATIONS OF IMMUNOTHERAPY

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized oncology but carry the risk of inducing autoimmune complications that necessitate an integrated rheumatology–oncology approach. This study employed a mixed-methods design to examine rheumatic immune-related adverse events (irAEs) among patients undergoing ICI therapy. Quantitative analyses were performed on patient cohorts receiving PD-1, PD-L1, CTLA-4, or combination therapies, capturing demographic variables, cancer subtypes, and autoimmune manifestations. Incidence rates revealed that up to 40% of patients developed irAEs, with arthritis, myositis, and vasculitis representing the most frequent complications. Logistic regression identified preexisting autoimmune disease and combination therapy as significant predictors of higher severity scores. Qualitative interviews with oncologists and rheumatologists highlighted challenges in early recognition, interdisciplinary communication, and balancing cancer control with autoimmune toxicity management. Results across nine structured tables and twenty-two figures—including line, bar, pie, scatter, hybrid, radar, heatmap, and bubble charts—demonstrated demographic variation, therapy patterns, severity distributions, and inter-variable correlations. Notably, chronic irAEs persisted in a subset of patients, emphasizing the need for long-term follow-up strategies. The methodological workflow (Figure 1) underscores the integration of patient monitoring, statistical modeling, and thematic analysis. Collectively, findings confirm that autoimmune events are not only prevalent but also diverse in presentation, reinforcing the necessity of multidisciplinary care models and personalized monitoring strategies. This study contributes to evolving frameworks for safer immunotherapy deployment, ensuring both sustained oncologic benefit and preservation of patient quality of life.